Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Brinzolamide 1% ophthalmic suspension AZOPT®
Brinzolamide 1% AZOPT · 1 trial · 2 indications
IOP (fluid pressure inside the eye) was assessed using Goldmann applanation tonometry and measured in millimeters of mercury (mmHg). A higher IOP can be a greater risk factor for developing glaucoma or glaucoma progression (leading to optic nerve damage). One eye (study eye) was used for the analysis.
| Arm | Type | Description |
|---|---|---|
| TravA/Brinz | EXPERIMENTAL | Dose Level A / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TravB/Brinz | EXPERIMENTAL | Dose Level B / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TravC/Brinz | EXPERIMENTAL | Dose Level C / Brinzolamide 1% ophthalmic suspension (fixed combination), 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| AZOPT | ACTIVE_COMPARATOR | Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) morning and night, with travoprost solution vehicle, 1 drop once daily in the treated eye(s) at night for 6 weeks |
| TRAV Z | ACTIVE_COMPARATOR | Brinzolamide suspension vehicle, 1 drop twice daily in the treated eye(s) morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| TRAV Z + AZOPT | ACTIVE_COMPARATOR | Brinzolamide 1% ophthalmic suspension, 1 drop twice daily in the treated eye(s) twice daily morning and night, with travoprost 0.004% ophthalmic solution, 1 drop once daily in the treated eye(s) at night, for 6 weeks |
| Name | Type | Description |
|---|---|---|
| Dose Level A / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Dose Level B / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Dose Level C / Brinzolamide 1% ophthalmic suspension | DRUG | Fixed combination |
| Brinzolamide 1% ophthalmic suspension AZOPT® | DRUG | - |
| Travoprost 0.004% ophthalmic solution TRAVATAN Z® | DRUG | - |
| Travoprost solution vehicle | DRUG | Inactive ingredients used for masking purposes |
| Brinzolamide suspension vehicle | DRUG | Inactive ingredients used for masking purposes |
Inclusion Criteria: * Diagnosed with open-angle glaucoma (including open-angle glaucoma with pseudoexfoliation or pigment dispersion) or ocular hypertension; * IOP within the protocol-specified range at both the Eligibility 1 and 2 Visits. Mean IOP must not be \>36 mmHg at any time point; * Able to...
Top 5 of 7 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Glaukos Corp | GKOS | 6 | PHASE3 | Gen 2 Travoprost Intracameral, Travoprost |
| SpyGlass Pharma, Inc. | SGP | 5 | PHASE3 | Bimatoprost System, BIM-DRS |
| AbbVie, Inc. | ABBV | 2 | PHASE3 | AGN-193408 |
| Amneal Pharmaceuticals, Inc. Class A | AMRX | 1 | PHASE3 | Bimatoprost ophthalmic solution |
| Regeneron Pharmaceuticals, Inc. | REGN | 1 | PHASE1 | REGN22530 |
Brinzolamide 1% AZOPT is an ophthalmic suspension being studied for glaucoma and ocular hypertension. It is a small molecule carbonic anhydrase inhibitor developed by Alcon Inc. (ticker ALC). The drug is in Phase 2 clinical development, with one completed trial in patients with open-angle glaucoma or ocular hypertension.
Brinzolamide 1% AZOPT targets carbonic anhydrase 2 (CA2). It is a CA2 inhibitor. By inhibiting this enzyme in the ciliary body, the drug reduces aqueous humor production, which can lower intraocular pressure in conditions such as glaucoma and ocular hypertension.
Brinzolamide 1% AZOPT is developed by Alcon Inc., which trades under the ticker ALC. Alcon is an eye care company focused on ophthalmic pharmaceuticals and devices. The drug is part of its glaucoma portfolio.
Brinzolamide 1% AZOPT is in Phase 2 clinical development. It is investigational and has not been approved by the FDA for the studied indications. One Phase 2 trial has been completed, and no active trials are currently listed.
Brinzolamide 1% AZOPT has been evaluated in a completed Phase 2 trial, NCT02140060, titled "6-Week Proof-of-Concept Study of Travoprost/Brinzolamide Ophthalmic Suspension in Subjects With Open-Angle Glaucoma or Ocular Hypertension." The randomized, double-blind, active-controlled study enrolled 327 participants aged 18 years and older.
Yes, Brinzolamide 1% AZOPT is also known as Brinzolamide 1% ophthalmic suspension AZOPT. Both names refer to the same product developed by Alcon Inc. for glaucoma and ocular hypertension.